Daito Pharmaceutical Co., Ltd.

4577.TJapan

15 filed reports · 300 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

¥50.7B

FY2026 · to May 31, 2026

up +0.0% vs ¥50.6B

Annual report

Net income

¥3.14B

FY2026 · to May 31, 2026

up +77.7% vs ¥1.77B

Annual report

Operating income

¥3.64B

FY2026 · to May 31, 2026

up +38.9% vs ¥2.62B

Annual report

Latest half year

Revenue

¥25.1B

H1 FY2026 · to Nov 30, 2025

up +2.3% vs ¥24.6B

Half-year report

Net income

¥1.22B

H1 FY2026 · to Nov 30, 2025

up +69.9% vs ¥718M

Half-year report

Operating income

¥1.63B

H1 FY2026 · to Nov 30, 2025

up +10.6% vs ¥1.47B

Half-year report

Filed reports

15 reports · Nov 2021 to May 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Annual · annual securities reportEDINET52,016May 2022 to May 2026
Half Year · quarterly securities reportEDINET3596Nov 2021 to Nov 2023
Q3 · quarterly securities reportEDINET3486Feb 2022 to Feb 2024
Half Year · half-year securities reportEDINET2517Nov 2024 to Nov 2025
Q1 · quarterly securities reportEDINET2323Aug 2022 to Aug 2023

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026annual securities report2026-05-312026-08-26684Open
FY2026 H1half-year securities report2025-11-302026-01-14321Open
FY2025annual securities report2025-05-312025-08-27336Open
FY2025 H1half-year securities report2024-11-302025-01-10196Open
FY2024annual securities report2024-05-312024-08-30325Open
FY2024 Q3quarterly securities report2024-02-292024-04-12187Open
FY2024 H1quarterly securities report2023-11-302024-01-12202Open
FY2024 Q1quarterly securities report2023-08-312023-10-13178Open
FY2023annual securities report2023-05-312023-08-30330Open
FY2023 Q3quarterly securities report2023-02-282023-04-13151Open
FY2023 H1quarterly securities report2022-11-302023-01-13200Open
FY2023 Q1quarterly securities report2022-08-312022-10-14145Open

Financial data

300 concepts · 3,938 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

GAAP300 concepts · 3,938 facts · May 2020 to May 2026

  • EPS (Basic)45 · May 2020 to May 2026
  • Equity-to-asset ratio, Key financial data37 · May 2020 to May 2026
  • Net Assets37 · May 2020 to May 2026
  • Ordinary profit (loss), Key financial data37 · May 2020 to May 2026
  • Revenue37 · May 2020 to May 2026
  • Total Assets37 · May 2020 to May 2026
  • Net assets, Key financial data34 · May 2020 to May 2026
  • Allowance for doubtful accounts-CA-by group32 · May 2021 to May 2026
  • Allowance for doubtful accounts-IOA-by group32 · May 2021 to May 2026
  • Capital surplus32 · May 2021 to May 2026
  • Cash and deposits32 · May 2021 to May 2026
  • Current portion of long-term borrowings32 · May 2021 to May 2026
  • Electronically recorded monetary claims - operating32 · May 2021 to May 2026
  • Electronically recorded obligations - operating32 · May 2021 to May 2026
  • Income taxes payable32 · May 2021 to May 2026
  • Intangible assets32 · May 2021 to May 2026
  • Investments and other assets32 · May 2021 to May 2026
  • Investment securities32 · May 2021 to May 2026
  • Long-term borrowings32 · May 2021 to May 2026
  • Merchandise and finished goods32 · May 2021 to May 2026
  • Other-CA32 · May 2021 to May 2026
  • Other-CL32 · May 2021 to May 2026
  • Other-IA32 · May 2021 to May 2026
  • Other-IOA32 · May 2021 to May 2026

Segments

Figures broken down by business line, region, product or another axis the company reports on.

No segment breakdowns.

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Daito Pharmaceutical Co., Ltd. (4577.T) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.

Daito Pharmaceutical Co., Ltd. (4577.T): FY2026 revenue ¥50.7B · FactIQ